Brief: Ampio Pharmaceuticals Receives Approval To Expand Enrollment Of Its AP-019 Phase Ii Study To India
15/06/2021 11:58
June 15 (Reuters) - Ampio Pharmaceuticals Inc AMPE.A :
* AMPIO PHARMACEUTICALS RECEIVES APPROVAL TO EXPAND
ENROLLMENT OF
ITS AP-019 PHASE II STUDY TO INDIA
* AMPIO PHARMACEUTICALS - PHASE II STUDY WILL UTILIZE
INHALED
AMPION TO TREAT THOSE SUFFERING FROM RESPIRATORY DISTRESS DUE TO
COVID-19
* AMPIO - DUE TO ONGOING POLITICAL UNREST IN ISRAEL &
SURROUNDING
REGION WITH REDUCTION IN COVID CASES, MADE STRATEGIC DECISION TO
DISCONTINUE AP-019 STUDY EFFORTS IN ISRAEL
Source text for Eikon: ID:nPnb1pKkXa
Further company coverage: AMPE.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ampio Pharmaceuticals
See all newsBrief: Ampio Announces Voluntary Delisting And SEC Deregistration
Brief: Ampio Provides Update On Results From Pre-IND Enabling Studies
Brief: Ampio Selects Ascendia Pharmaceuticals, Inc. To Provide CDMO Services To Support Clinical Development Of OA-201
Brief: Ampio Pharmaceuticals Announces Reverse Stock Split
Brief: Ampio Pharmaceuticals Inc - Holds Approximately $1.25 Million In A Deposit Account At Silicon Valley Bank